The Function of tPA in Fibrinolysis is Analogous to the Starter of An Automobile
Victor Gurewich
Abstract
Open-access reader
Victor Gurewich
Abstract
Open-access reader
Therapeutic fibrinolysis has used tissue plasminogen activator (tPA) as the fibrinolytic of choice ever since tPA was given FDA approval for the treatment of acute myocardial infarction (AMI) in 1987. This was followed in few years by its approval for ischemic stroke and tPA re-mains the treatment today based on an assumption that tPA is responsible for biological fibrinolysis. However, the evidence for this was never strong but has remained unchallenged for the past 33 years.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Therapeutic fibrinolysis has used tissue plasminogen activator (tPA) as the fibrinolytic of choice ever since tPA was given FDA approval for the treatment of acute myocardial infarction (AMI) in 1987. This was followed in few years by its approval for ischemic stroke and tPA re-mains the treatment today based on an assumption that tPA is responsible for biological fibrinolysis. However, the evidence for this was never strong but has remained unchallenged for the past 33 years.
Key concepts: Fibrinolysis, Tissue plasminogen activator, Medicine, Myocardial infarction, Fibrinolytic agent, Plasminogen activator, Internal medicine, Cardiology